Should one be buying Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)?

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) moved down -3.71% and closed its last trading session at $10.38. This Medical Sector stock currently has the Market Capitalization of 2.08 Billion. The Average Volume for the stock is measured as 6.53 Million. The Stock has a 52-Week High of $14.34 and 52-Week Low of $4.37 following the dates, it touched its 52-Week High on Oct 10, 2016 and 52-Week Low on Feb 11, 2016. Currently, the Return on Assets value for the trailing twelve months is -10.5% with the Return on Equity and Return on Investment of 68.8% and -62.9% respectively. This firm currently has YTD (year to date) performance of 66.08 Percent which is awesome. The Short Ratio for the stock is 4.43.

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) Price to Earnings (P/E) ratio is 0. EPS or Earning per Share stands at $-0.33. The TTM operating margin is -99.5 percent.

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) is due to report its Earnings on Tue 1 Nov (In 9 Days). The estimated EPS for the current quarter is said to be $-0.19. Following Earnings result, share price were DOWN 15 times out of last 26 Qtrs. The stock has added about 23.3% since it reported its last earnings. The Closing price of Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) at Last Earnings was $8.42 as compared to the previous closing price of $10.78. The Predicted Move on the 7th day after Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) will release its earnings at about 6%.

By Looking at Earnings History, Out of 12 Quarters when the Earnings were reported, Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) beats earnings by 58%, The Stock Missed Earnings  5  times and has met earnings  0 times.

Earnings History:

We will discuss the past Quarters Earnings below:

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) reported its previous quarter on 07/28/2016 where it reported the Actual Earnings of $0.56. The Closing price before the company posted its earnings was $8.42. The Stock surged on the very next day of earnings and maintained its stock price at $9.47 by showing a % change of 12.47 percent from its previous closing price. The Next Day Volume after Earnings was reported as 16.73 Million. On the 7th day After Earnings Report, the stock hit its share price as $9.93 by showing 17.93% increase from the Stock price Before Earnings were reported.

On 05/10/2016, the stock reported the EPS of $-0.28 where Analysts were projecting the EPS to be $-0.24 showing a difference of $-0.04. Thus Surprise Factor was there with -16.7 percent. Before Earnings Announcement on 05/10/2016, the firm had its stock price of $7.18. And immediately on the next day after earnings announcement, the stock inclined 6.41% and closed its trading session at $7.64. On 7th Day after earnings release, Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) surged to 7.8% from $7.18 to $7.74.

On 02/23/2016, Analysts were suspecting EPS of $-0.32/share where Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) reported its Actual EPS of $-0.32. Thus showing a Surprise of 0 percent. The Closing Price of the stock before earnings was $5.08 while on the Next day the stock closed its trading session at $4.85 with a percentage change of -4.53% from the price of 5.08 before Earnings. The Stock Closing Price on the 7th day of earnings was $5.46.

Company Profile:

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.